
Artificial Intelligence-Based Prediction of Cognitive Frailty: A clinical Data Approach.
Author(s) -
S. O Salami,
F. Z Rokhani,
M Aashiq,
S.A. Ahmad,
M.P. Tan,
Y Zhao
Publication year - 2025
Publication title -
ieee access
Language(s) - English
Resource type - Magazines
SCImago Journal Rank - 0.587
H-Index - 127
eISSN - 2169-3536
DOI - 10.1109/access.2025.3595187
Subject(s) - aerospace , bioengineering , communication, networking and broadcast technologies , components, circuits, devices and systems , computing and processing , engineered materials, dielectrics and plasmas , engineering profession , fields, waves and electromagnetics , general topics for engineers , geoscience , nuclear engineering , photonics and electrooptics , power, energy and industry applications , robotics and control systems , signal processing and analysis , transportation
Cognitive frailty (CF), defined as the co-existence of physical frailty and cognitive impairment without dementia, has two subtypes: reversible cognitive frailty (RCF) and potentially reversible cognitive frailty (PRCF). This study aimed to develop machine learning models for the early prediction of CF by incorporating both RCF and PRCF into a unified framework. Data from 2,173 participants were sourced from the AGELESS and MELoR cohort studies, including clinical, blood, urine, and health status information. Participants were grouped into six CF categories based on the FRAIL scale and MoCA scores from 2020 and 2022. Seven machine learning models, SVM, LR, KNN, RF, CART, LDA, and GNB, were trained using clinical, blood, and urine datasets. Clinical variables outperformed other data types, with SVM, LR, and CART models achieving 95% accuracy and AUC scores of 1.0, while blood- and urine-based models showed lower performance (AUCs of 0.8 and 0.89, respectively). F1 scores and ROC analysis confirmed the robustness of the clinical models, and cross-validation showed consistent performance on unseen data, indicating no overfitting. These findings highlight the superior predictive power of clinical variables for identifying both subtypes of CF, supporting their potential for use in early, accurate diagnosis. Nonetheless, external validation using independent cohorts is recommended to ensure broader applicability.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom